Doxycycline Hyclate

Introduction Overview

Generic Name

Doxycycline Hyclate

Brand Name

No specific brand listed; available also as Vibramycin, Monodox, Doryx, Oracea, among others

Dosage Form

Capsule for oral administration

Drug Class

Miscellaneous antimalarials, Tetracyclines

Pharmacokinetics

Absorption:
Doxycycline Hyclate exhibits virtually complete absorption from the gastrointestinal tract following oral administration, with bioavailability nearly 100%. Peak serum concentrations of approximately 2.6 mcg/mL are reached within 2 hours post-dose after a 200 mg oral administration, decreasing to 1.45 mcg/mL at 24 hours. Unlike other tetracyclines, doxycycline’s absorption is not significantly affected by food or concurrent ingestion of dairy products, making it more flexible for dosing with or without meals. However, binding with calcium or aluminum-containing compounds may reduce absorption.

Distribution:
Doxycycline is characterized by a high degree of lipoid solubility, allowing broad tissue penetration, including respiratory tract tissues, prostate, and intracellular compartments. It has a low affinity for calcium binding compared to other tetracyclines, thus resulting in reduced deposition in bones and teeth. The drug is approximately 80-90% bound to serum proteins, mainly albumin. It crosses the placenta and is found in fetal tissues, and is excreted in breast milk, though the extent of infant absorption remains uncertain. Doxycycline has a large volume of distribution attributable to its tissue penetration.

Metabolism:
Doxycycline undergoes limited hepatic metabolism, with the majority of the drug remaining unmetabolized. This minimal metabolic alteration results in a predictable pharmacokinetic profile without the generation of active or toxic metabolites. The drug demonstrates high stability in human serum and does not degrade into epianhydro forms, preserving its antibacterial activity.

Elimination:
Excretion occurs primarily through biliary and renal routes. Approximately 40% of a dose is excreted in urine within 72 hours in subjects with normal renal function, with substantial elimination also through the feces via biliary secretion. In patients with severe renal impairment (creatinine clearance below 10 mL/min), renal excretion may drop to between 1-5% over 72 hours, yet serum half-life (approximately 18-22 hours) remains unchanged. This stability allows for dosing without adjustment in renal insufficiency. Hemodialysis does not significantly alter elimination. The elimination half-life supports twice-daily or once-daily dosing regimens depending on indication and severity.

Dosage Forms

Available Dosage Forms:
Doxycycline Hyclate is supplied as hard gelatin capsules for oral administration in strengths equivalent to 50 mg and 100 mg doxycycline (anhydrous). Capsules are formulated with inactive ingredients including lactose monohydrate, microcrystalline cellulose, magnesium stearate, gelatin, FD&C Blue No. 1, titanium dioxide, and various dyes for capsule shell and print inks.

Dosages for Adults and Adolescents:
- Initial dosing for most infections is 200 mg on day one (100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.
- For severe or chronic infections, 100 mg every 12 hours is recommended.
- Specific regimens vary by infection, e.g., 100 mg twice daily for 7-10 days for chlamydial and gonorrheal infections.
- For anthrax post-exposure prophylaxis, adults receive 100 mg twice daily for 60 days.
- Malaria prophylaxis dose for adults is 100 mg once daily beginning 1-2 days prior to travel and continuing 4 weeks post-exposure.

Specific Patient Populations:
- Pediatric patients under 8 years should receive doxycycline only for severe, life-threatening infections due to risks of tooth discoloration and bone growth interference.
- Pediatric dosing for severe infections is 2.2 mg/kg every 12 hours; for less severe disease, initial dose 4.4 mg/kg on day one, then 2.2 mg/kg once or twice daily maintenance.
- Children 45 kg or more may receive adult dosing.
- Renal impairment does not require dosage adjustment due to limited renal elimination alteration.
- In patients with swallowing difficulties or gastrointestinal irritation, administration with fluids and possibly food or milk is recommended to minimize esophageal irritation.

Mechanism Of Action

Doxycycline Hyclate exerts its antimicrobial effect primarily through inhibition of bacterial protein synthesis. It binds reversibly to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex, thereby inhibiting the addition of amino acids to the growing peptide chain. This inhibition halts bacterial translation and protein production, leading predominantly to a bacteriostatic effect.

At the cellular level, doxycycline interferes with bacterial ribosomal function, without affecting mammalian ribosomes, attributable to differences in ribosomal structure. Its lipophilicity facilitates entry into various tissues and intracellular compartments, enhancing activity against intracellular pathogens such as Chlamydia, Rickettsiae, and Mycoplasma species.

The drug exhibits broad-spectrum activity against a diverse range of Gram-positive and Gram-negative bacteria, anaerobes, atypical pathogens, as well as certain parasites like Plasmodium falciparum’s asexual erythrocytic forms. The mechanism for antimalarial activity is not completely elucidated but may involve interference with apicoplast protein synthesis or other parasite-specific pathways.

Resistance mechanisms include efflux pumps and ribosomal protection proteins that reduce doxycycline’s binding to bacterial ribosomes, often resulting in cross-resistance among tetracycline antibiotics. Clinically, this necessitates susceptibility testing in some infections.

Clinical studies have demonstrated doxycycline's efficacy due to this mechanism in treating respiratory tract infections, sexually transmitted infections, rickettsial diseases, and malaria prophylaxis. Compared to other tetracyclines, doxycycline has superior bioavailability, longer half-life, and better tissue penetration, contributing to its broad clinical utility.

Pharmacological Actions

Bacteriostatic antibiotic action by inhibition of protein synthesis via 30S ribosomal binding
Broad-spectrum antimicrobial activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria
Antiparasitic activity against Plasmodium falciparum asexual erythrocytic forms for malaria prophylaxis
High oral bioavailability and stable serum concentrations enabling convenient dosing schedules
High lipophilicity allowing intracellular penetration and efficacy against intracellular pathogens
Minimal metabolism with predictable pharmacokinetics and reduced drug-drug interactions
Excreted in active form through both renal and biliary routes, maintaining effectiveness in renal impairment
Resistance mitigation through prudent use to avoid bacterial resistance development
Anti-inflammatory properties suggested in some skin conditions such as acne
Competitive interference with bacterial ribosomal function without effect on human mitochondrial protein synthesis

Therapeutic Or Clinical Uses

Treatment of rickettsial infections including Rocky Mountain spotted fever, typhus, Q fever, and tick fevers
Respiratory tract infections caused by Mycoplasma pneumoniae and Streptococcus pneumoniae
Sexually transmitted infections including chlamydial infections, lymphogranuloma venereum, and nongonococcal urethritis
Treatment of infections caused by susceptible gram-negative bacteria including Haemophilus influenzae and Escherichia coli
Anthrax treatment and post-exposure prophylaxis, including inhalational anthrax
Prophylaxis of malaria in short-term travelers to regions with resistant Plasmodium falciparum strains
Treatment of plague, tularemia, chancroid, brucellosis, granuloma inguinale, and bartonellosis
Used as alternative agent in penicillin-allergic patients for syphilis, gonorrhea, listeriosis, and actinomycosis
Adjunctive treatment of severe acne vulgaris
Adjunctive therapy in acute intestinal amebiasis
Management of relapsing fever and other spirochetal infections
Treatment of infections caused by aerobic actinomycetes, including nocardiae
Treatment of inclusion conjunctivitis caused by Chlamydia trachomatis
Empiric therapy for respiratory and urinary tract infections pending susceptibility results
Use in veterinary medicine for canine infections (outside human indications)

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, diarrhea, anorexia, glossitis, and dysphagia
Esophagitis and esophageal ulcerations, particularly if ingested without adequate fluids or before lying down
Photosensitivity reactions presenting as exaggerated sunburn or skin eruptions
Rare hepatotoxicity potentially presenting as elevated liver enzymes or hepatitis
Superficial discoloration of permanent teeth and enamel hypoplasia when used during tooth development
Hypersensitivity reactions including urticaria, angioedema, anaphylaxis, serum sickness, and drug reaction with eosinophilia and systemic symptoms (DRESS)
Severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and exfoliative dermatitis
Hematologic effects including hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia
Neurological effects such as intracranial hypertension (pseudotumor cerebri), headache, blurred vision, and dizziness
Renal toxicity evidenced by increased blood urea nitrogen (BUN), dose-related
Psychiatric manifestations including depression, anxiety, suicidal ideation, insomnia, hallucinations, and abnormal dreams
Skin hyperpigmentation and fixed drug eruptions with possible worsening on re-exposure
Jarisch-Herxheimer reaction in spirochetal infections, manifesting as fever and inflammatory symptoms
Bulging fontanels reported in infants
Possible adrenal and thyroid gland hyperplasia observed in animal studies with long-term use

Precautions

Avoid unnecessary use to reduce development of drug-resistant bacteria
Use with caution in pediatric patients under 8 years due to permanent tooth discoloration and enamel hypoplasia risks; only when benefits outweigh risks
Advise patients to avoid excessive sunlight or ultraviolet exposure due to risk of photosensitivity
Ensure adequate fluid intake during administration to prevent esophageal irritation and ulceration
Discontinue immediately if severe skin reactions occur and initiate appropriate treatment
Monitor patients for signs of Clostridioides difficile associated diarrhea (CDAD), especially with prolonged use
Use cautiously in patients with hepatic impairment and monitor liver function tests during long-term therapy
Adjust anticoagulant dosing as doxycycline may depress plasma prothrombin activity
Avoid concomitant use with isotretinoin due to increased risk of intracranial hypertension
Counsel patients about possible diminished efficacy of oral contraceptives during tetracycline therapy
Consider alternative or additional therapy in renal impairment is typically not necessary as doxycycline pharmacokinetics are stable
Superinfections with fungi or nonsusceptible organisms may occur; discontinue therapy if they develop
Patients should complete full prescribed course even if symptoms improve early to prevent resistance
Pregnant women should be apprised of fetal risk; drug generally avoided unless benefits justify potential risk
Lactating women should weigh benefits against potential risks to infant; limited data available

Warnings

Permanent discoloration (yellow-gray-brown) of teeth and enamel hypoplasia when used during tooth development period
Photosensitivity reactions can be severe; discontinue therapy if skin erythema or rash develops
Risk of Clostridioides difficile associated diarrhea ranging from mild diarrhea to fatal colitis; consider diagnosis if diarrhea develops during or post-therapy
Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis have been reported
Intracranial hypertension (pseudotumor cerebri) presenting with headache, vision changes, and papilledema; may cause permanent visual loss
Overdosage may lead to increased side effects but dialysis does not enhance elimination
Use during pregnancy and lactation carries potential risks to fetus and infant; use only if benefits justify risks
Avoid use in children under 8 years unless severe or life-threatening infection with no alternatives exists
Hepatotoxicity and renal toxicity have been rarely reported; monitor in at-risk populations
Concomitant use with isotretinoin is contraindicated due to additive risk of intracranial hypertension
May reduce efficacy of oral contraceptives
Use caution when co-administering with anticoagulants due to potential enhancement of anticoagulant effect
Use caution in patients with a history of hypersensitivity to tetracyclines
Avoid use with antacids or minerals containing aluminum, calcium, magnesium, or iron which impede absorption
Photosensitizing potential requires patient counseling regarding prevention and early detection

Contraindication

Known hypersensitivity to doxycycline or any other tetracycline-class antibiotic
Use during tooth development (last half of pregnancy, infancy, and childhood under 8 years) except in severe or life-threatening infections when no alternatives are available
Concurrent use with isotretinoin due to risk of pseudo tumor cerebri
Patients with a history of severe liver impairment or hepatic dysfunction related to tetracycline use
Use contraindicated in patients with known allergy to tetracyclines or components of the capsule formulation
Contraindicated in cases where the drug-resistant bacterial infections are identified or highly suspected
Avoid use in pregnancy unless potential maternal benefit outweighs fetal risk
Not recommended for viral infections such as the common cold or flu
Avoid use with other drugs that may increase risk of photosensitivity without appropriate monitoring
Contraindicated in patients with esophageal abnormalities predisposing to delayed esophageal transit
Avoid in patients with hypersensitivity to any inactive ingredients contained in the formulation

Drug Interactions

Absorption impaired by antacids and supplements containing aluminum, calcium, magnesium, or iron
Bismuth subsalicylate reduces tetracycline absorption, including doxycycline
Barbiturates, carbamazepine, and phenytoin may accelerate metabolism and decrease doxycycline half-life
Concurrent use with penicillin may reduce bactericidal action due to doxycycline’s bacteriostatic effect
May reduce effectiveness of oral contraceptives, necessitating alternative contraception methods
Tetracyclines may potentiate the anticoagulant effect of warfarin and other oral anticoagulants
Potential interference with urinary catecholamine fluorescence tests causing false elevations
Concurrent isotretinoin use contraindicated due to increased risk of pseudotumor cerebri
Possible additive nephrotoxicity if used with other nephrotoxic agents in susceptible patients
May interact with systemic retinoids and increase incidence of adverse neurological effects
Use with caution when combined with drugs metabolized by cytochrome P450 due to potential pharmacokinetic variability
Concurrent use with cation-containing medications requires separation of dosing times to maintain doxycycline efficacy
Co-administration with other photosensitizing agents may increase risk of phototoxicity
Doxycycline may decrease plasma prothrombin activity, necessitating coagulation monitoring
Interaction with live bacterial vaccines is possible; take caution when administering tetracyclines concurrently

Preparations Of The Drug

Oral hard gelatin capsules containing doxycycline hyclate equivalent to 50 mg or 100 mg doxycycline (anhydrous)
Capsules contain inactive ingredients including lactose monohydrate, microcrystalline cellulose, magnesium stearate
Capsule shells formulated with gelatin, FD&C Blue No. 1, titanium dioxide, and various coloring and printing agents (shellac, iron oxide black, n-butyl alcohol, propylene glycol, alcohol, FD&C Blue No. 2, FD&C Red No. 40, D&C Yellow No. 10)
Packaging varies with cartons of 30 or 50 capsules, each capsule individually enclosed in blister packs
Stored at controlled room temperature 20° to 25°C (68° to 77°F), protected from light and moisture
Dispensed in tight, light-resistant containers with child-resistant closures, intended for institutional use only
Available in branded formulations such as Vibramycin, Monodox, Doryx, Oracea, and generic equivalents
Formulation designed for oral administration with consideration to maximize bioavailability and reduce GI irritation
Other doxycycline formulations include tablets, delayed-release capsules, oral liquids, but doxycycline hyclate commonly available as capsules
No parenteral formulation for doxycycline hyclate; intravenous formulations may use doxycycline monohydrate or other salt forms
Inactive ingredients selected for stability, ease of ingestion, and minimization of allergic reactions